PGXIS is looking to build its pipeline of candidate drug assets, via in-licensing, co-development or other partnering arrangement, where the assets will benefit both from our broad expertise in drug development and from our specialised expertise in pharmacogenetics. We are always looking to increase our own development portfolio through in-licensing and partnership agreements.

There are many advantages of partnering with PGXIS. For example, we bring an expert eye to the development planning using existing pharmacogenetic knowledge. In addition, our siRNA technology allows application of this technology to new areas where pharmacogenetic knowledge is currently limited.

We are particularly keen to identify compounds in late pre-clinical development, as incorporating PGx into the clinical planning from an early stage will maximise the beneficial impact of the technology and give rise to the greatest probability of success in the clinic.

As pharmacogenomics has been shown to reduce attrition in drug development, we are keen to identify compounds that have failed in clinical studies so that we can apply our expertise to re-activate these programmes.

We want to make an impact in oncology and neurology, and many other therapeutic areas where modern genetics has established key genes important for the disease aetiology, such as Alzheimer's disease, Parkinson's disease, type II diabetes and obesity. We also want to be involved in diseases with childhood onset.

Please contact us so we can meet to discuss your compounds and your ideas.
Advantages of Partnering with PGXIS
Partnering with or out-licensing to PGXIS during drug discovery and development has distinct advantages:
  •   PGx in Phase I studies to ensure correct dosing in proof of concept studies, and reduce the risk of adverse events due to over-exposure to medicines in poor-metabolizers'
  •   Using the cutting edge siRNA technology developed by CytoPathfinder Inc, to identify the genes that are relevant for drug activity.
  •   Design of Phase II proof of concept studies incorporating PGx to maximise the opportunity of showing efficiency in a defined sub-group of patients
    • Together, application of pharmacogenomics can maximise the chance of showing efficiency in the critical Phase II studies, which are typically the largest source of attrition in the drug development pipeline.
    There are a growing number of examples where pharmacogenomic data have allowed a compound to progress in development which would otherwise have been terminated. (For a recent example, see the information on bapinezemab from Elan/Wyeth
    PGXIS is especially keen to apply its expertise to help progress compounds which have failed in clinical development. This is an area that could have significant impact on patient's treatment.
    If you have a compound which has failed during development, please contact us so we can meet to discuss your compounds.